RETA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 18, 2022 in the Class Action Filed on Behalf of Reata Pharmaceuticals, Inc. Shareholders

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Reata securities, and/or sold Reata put options, between November 9, 2020 and December 8, 2021, inclusive.
Lead Plaintiff Deadline: February 18, 2022
No obligation or cost to you.

Learn more about your recoverable losses in RETA:
https://www.kleinstocklaw.com/pslra-1/reata-pharmaceuticals-inc-loss-submission-form-2?id=23407&from=4

Reata Pharmaceuticals, Inc. NEWS - RETA NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Reata Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) as a result, there was a material risk that Reata's New Drug Application would not be approved; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Reata, you have until February 18, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Reata securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the RETA lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/reata-pharmaceuticals-inc-loss-submission-form-2?id=23407&from=4.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
www.kleinstocklaw.com

SOURCE The Klein Law Firm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED